# Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery

> **NCT00471484** · PHASE2 · UNKNOWN · sponsor: **National Cancer Centre, Singapore** · enrollment: 54 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa-2b
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** fluorouracil
- **DRUG:** oxaliplatin
- **OTHER:** diagnostic laboratory biomarker analysis
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** biopsy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00471484
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2011-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471484, "Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00471484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*